A Phase 2 trial of MYK-461 in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM)
Phase of Trial: Phase II
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Mavacamten (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Adverse reactions; Therapeutic Use
- Acronyms EXPLORER-HCM
- Sponsors MyoKardia
- 07 Aug 2017 according to a MyoKardia media release, company look forward to discussing with FDA the potential for this study to serve as a pivotal study.
- 07 Aug 2017 Planned number of patients changed from 100 to 250, according to a MyoKardia media release.
- 07 Aug 2017 According to a MyoKardia media release, this study is expected to initiate by the end of 2017.